Dr. Philip Arlen, CEO, to give two scientific talks in Tokyo, Japan, December 14th – 15th, 2023
Dr. Philip M. Arlen, President & CEO of Precision Biologics, Inc. will deliver a scientific...
Dr. Philip M. Arlen, President & CEO of Precision Biologics, Inc. will deliver a scientific...
Natural killer (NK) cells are cellular components of the innate immune system that can recognize...
Precision Biologics presents new data from ongoing NEO-201 clinical trial at the Society for Immunotherapy...
Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent...
Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver...
A poster will be presented in person at the American Association for Cancer Research (AACR)...
Precision Biologics, Inc. publishes data and analysis from recent First-In-Human Phase 1 Clinical Trial With...
Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...
READ ARTICLE
Precision Biologics, Inc. publishes paper on latest findings of the unique target that NEO-201 recognizes,...